癌細胞特異糖鎖抗原による慢性関節リウマチ患者に対する感作療法

据我们报道，在严重类风湿关节炎（RA）患者受累关节附近的骨骺骨髓中发现了一种新的具有癌胎膜标记物二聚体Lex （di-Lex; III3FucV3FucnLc6）的骨髓细胞群。类风湿性关节炎患者接受皮内注射（id）的脂质体或高分子量糖蛋白，或肿瘤相关碳水化合物抗原（TCA），含有相同的碳水化合物表位的双lex。在注射id时，骨骺髓样细胞减少或消失。在id注射的随机试验中，在临床和实验室条件下观察发现，适当剂量的di-Lex （III3FucnLc4）治疗6个月后，63%（17/27）的患者有改善，而采用相同方案治疗TCA的患者有72%（31/43）有改善。而注射单分子Lex则无明显影响。

As reported by us, a new myeloid cell population with an oncofetal membrane marker, dimeric Lex (di-Lex ; III3FucV3FucnLc6) , was found in the epiphyseal bone marrow adjacent to the involved joints of patients with severe rheumatoid arthritis (RA) .Patients with RA recieved intradermal (id) injections of di-Lex incorporated in liposome or of high molecular weight glycoprotein, or tumor assosiated carbohydrate antigen (TCA) , containing the same carbohydrate epitope as di-Lex. The epiphyseal myeloid cells were reduced or sometimes eliminated during id injection. In random trials of id injection, observation under clinical and laboratory conditions showed improvement in 63% (17/27) of the patients treated for 6 months with appropriate doses of di-Lex (III3FucnLc4) , and in 72% (31/43) of those treated with an identical protocol for TCA.However, id injection with monomeric Lex had no effect.